{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:58:32Z","timestamp":1787795912512,"version":"build-2784847793"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Fundamental Research Fund of Xi\u2019an Jiaotong University","award":["xzy012023115"],"award-info":[{"award-number":["xzy012023115"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-02019-6","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:09:11Z","timestamp":1761034151000},"page":"2017-2026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world safety assessment of ublituximab: a pharmacovigilance analysis based on the FDA adverse event reporting system"],"prefix":"10.1007","volume":"47","author":[{"given":"Sen","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaidi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"2","key":"2019_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u201380. https:\/\/doi.org\/10.1056\/NEJMra1401483.","journal-title":"N Engl J Med"},{"issue":"11","key":"2019_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103449","volume":"22","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wang J, Feng J. Multiple sclerosis and pregnancy: pathogenesis, influencing factors, and treatment options. Autoimmun Rev. 2023;22(11):103449. https:\/\/doi.org\/10.1016\/j.autrev.2023.103449.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"2019_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/brain\/aww258","volume":"140","author":"J Correale","year":"2017","unstructured":"Correale J, Gait\u00e1n MI, Ysrraelit MC, et al. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017;140(3):527\u201346. https:\/\/doi.org\/10.1093\/brain\/aww258.","journal-title":"Brain"},{"issue":"10076","key":"2019_CR4","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/s0140-6736(16)30959-x","volume":"389","author":"WJ Brownlee","year":"2017","unstructured":"Brownlee WJ, Hardy TA, Fazekas F, et al. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(16)30959-x.","journal-title":"Lancet"},{"issue":"1","key":"2019_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"R Dobson","year":"2019","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis\u2014a review. Eur J Neurol. 2019;26(1):27\u201340. https:\/\/doi.org\/10.1111\/ene.13819.","journal-title":"Eur J Neurol"},{"issue":"10130","key":"2019_CR6","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/s0140-6736(18)30481-1","volume":"391","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391(10130):1622\u201336. https:\/\/doi.org\/10.1016\/s0140-6736(18)30481-1.","journal-title":"Lancet"},{"issue":"3","key":"2019_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","volume":"84","author":"AK Carlson","year":"2024","unstructured":"Carlson AK, Amin M, Cohen JA. Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability. Drugs. 2024;84(3):285\u2013304. https:\/\/doi.org\/10.1007\/s40265-024-02011-w.","journal-title":"Drugs"},{"issue":"2","key":"2019_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjh.14534","volume":"177","author":"A Sawas","year":"2017","unstructured":"Sawas A, Farber CM, Schreeder MT, et al. A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017;177(2):243\u201353. https:\/\/doi.org\/10.1111\/bjh.14534.","journal-title":"Br J Haematol"},{"issue":"5","key":"2019_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40265-023-01854-z","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee A. Ublituximab: first approval. Drugs. 2023;83(5):455\u20139. https:\/\/doi.org\/10.1007\/s40265-023-01854-z.","journal-title":"Drugs"},{"key":"2019_CR10","doi-asserted-by":"publisher","first-page":"1548292","DOI":"10.3389\/fimmu.2025.1548292","volume":"16","author":"R Vincken","year":"2025","unstructured":"Vincken R, Armend\u00e1riz-Mart\u00ednez U, Ruiz-S\u00e1enz A. ADCC: the rock band led by therapeutic antibodies, tumor and immune cells. Front Immunol. 2025;16:1548292. https:\/\/doi.org\/10.3389\/fimmu.2025.1548292.","journal-title":"Front Immunol"},{"key":"2019_CR11","doi-asserted-by":"publisher","first-page":"1275904","DOI":"10.3389\/fimmu.2023.1275904","volume":"14","author":"M Fantini","year":"2023","unstructured":"Fantini M, Arlen PM, Tsang KY. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. Front Immunol. 2023;14:1275904. https:\/\/doi.org\/10.3389\/fimmu.2023.1275904.","journal-title":"Front Immunol"},{"key":"2019_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841859","volume":"13","author":"R Hullsiek","year":"2022","unstructured":"Hullsiek R, Li Y, Snyder KM, et al. Examination of IgG Fc receptor CD16A and CD64 expression by canine leukocytes and their ADCC activity in engineered NK cells. Front Immunol. 2022;13:841859. https:\/\/doi.org\/10.3389\/fimmu.2022.841859.","journal-title":"Front Immunol"},{"issue":"1","key":"2019_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22\u201333. https:\/\/doi.org\/10.4161\/mabs.22771.","journal-title":"MAbs"},{"issue":"1","key":"2019_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/leu.2013.240","volume":"28","author":"M Le Garff-Tavernier","year":"2014","unstructured":"Le Garff-Tavernier M, Herbi L, de Romeuf C, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia. 2014;28(1):230\u20133. https:\/\/doi.org\/10.1038\/leu.2013.240.","journal-title":"Leukemia"},{"issue":"3","key":"2019_CR15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","volume":"27","author":"E Fox","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420\u20139. https:\/\/doi.org\/10.1177\/1352458520918375.","journal-title":"Mult Scler"},{"issue":"8","key":"2019_CR16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40263-022-00939-9","volume":"36","author":"S Faissner","year":"2022","unstructured":"Faissner S, Gold R. Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments. CNS Drugs. 2022;36(8):803\u201317. https:\/\/doi.org\/10.1007\/s40263-022-00939-9.","journal-title":"CNS Drugs"},{"key":"2019_CR17","doi-asserted-by":"publisher","first-page":"1527102","DOI":"10.3389\/fimmu.2025.1527102","volume":"16","author":"R Berkovich","year":"2025","unstructured":"Berkovich R, Calkwood J, Crayton H, et al. Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series. Front Immunol. 2025;16:1527102. https:\/\/doi.org\/10.3389\/fimmu.2025.1527102.","journal-title":"Front Immunol"},{"key":"2019_CR18","unstructured":"TG Therapeutics, Inc. BRIUMVI\u2122 (ublituximab-xiiy) injection, for intravenous use: US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761238s011lbl.pdf. Accessed 14 Mar 2025."},{"issue":"4","key":"2019_CR19","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/s2352-3026(20)30433-6","volume":"8","author":"JP Sharman","year":"2021","unstructured":"Sharman JP, Brander DM, Mato AR, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021;8(4):e254\u201366. https:\/\/doi.org\/10.1016\/s2352-3026(20)30433-6.","journal-title":"Lancet Haematol"},{"issue":"8","key":"2019_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201904.","journal-title":"N Engl J Med"},{"issue":"3","key":"2019_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11096-025-01867-6","volume":"47","author":"X Wen","year":"2025","unstructured":"Wen X, Cai L, Gao A, et al. Pharmacovigilance analysis of drug-induced hypofibrinogenemia using the FDA adverse event reporting system. Int J Clin Pharm. 2025;47(3):755\u201366. https:\/\/doi.org\/10.1007\/s11096-025-01867-6.","journal-title":"Int J Clin Pharm"},{"key":"2019_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01896-1","author":"K Zhao","year":"2025","unstructured":"Zhao K, Xiao S, Zhao Y, et al. Real-world safety of deucravacitinib: insights from the food and drug administration adverse event reporting system. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01896-1.","journal-title":"Int J Clin Pharm"},{"key":"2019_CR23","doi-asserted-by":"publisher","first-page":"1500810","DOI":"10.3389\/fphar.2024.1500810","volume":"15","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Yao Y, Zhu L. Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol. 2024;15:1500810. https:\/\/doi.org\/10.3389\/fphar.2024.1500810.","journal-title":"Front Pharmacol"},{"key":"2019_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01914-2","author":"S Wang","year":"2025","unstructured":"Wang S, Wang J, Zhang H. Pancreatitis associated with BRAF inhibitors: a disproportionality analysis based on the Food and Drug Administration adverse event reporting system. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01914-2.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"2019_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah NH, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010\u201321. https:\/\/doi.org\/10.1038\/clpt.2012.50.","journal-title":"Clin Pharmacol Ther"},{"key":"2019_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100887","volume":"36","author":"EB Cone","year":"2021","unstructured":"Cone EB, Reese S, Marchese M, et al. Cardiovascular toxicities associated with abiraterone compared to enzalutamide-a pharmacovigilance study. EClinicalMedicine. 2021;36:100887. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100887.","journal-title":"EClinicalMedicine"},{"issue":"8","key":"2019_CR27","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1097\/js9.0000000000002592","volume":"111","author":"Y Jiao","year":"2025","unstructured":"Jiao Y, Liu ZC, Liu YH, et al. Unveiling the hidden risks: analysis of adverse drug reactions associated with probiotics from the FAERS database\u2014quality improvement study. Int J Surg. 2025;111(8):5262\u20137. https:\/\/doi.org\/10.1097\/js9.0000000000002592.","journal-title":"Int J Surg"},{"key":"2019_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01980-6","author":"H Tan","year":"2025","unstructured":"Tan H, Chen X, Ou X, et al. Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database. Int J Clin Pharm. 2025. https:\/\/doi.org\/10.1007\/s11096-025-01980-6.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"2019_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11096-025-01869-4","volume":"47","author":"Q Gong","year":"2025","unstructured":"Gong Q, Zhang L, Wu H, et al. Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system. Int J Clin Pharm. 2025;47(3):767\u201374. https:\/\/doi.org\/10.1007\/s11096-025-01869-4.","journal-title":"Int J Clin Pharm"},{"issue":"7\u20138","key":"2019_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","volume":"14","author":"M Hauben","year":"2009","unstructured":"Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7\u20138):343\u201357. https:\/\/doi.org\/10.1016\/j.drudis.2008.12.012.","journal-title":"Drug Discov Today"},{"issue":"1","key":"2019_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/15476910801897433","volume":"5","author":"M Wing","year":"2008","unstructured":"Wing M. Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxicol. 2008;5(1):11\u20135. https:\/\/doi.org\/10.1080\/15476910801897433.","journal-title":"J Immunotoxicol"},{"issue":"14","key":"2019_CR32","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1614598.","journal-title":"N Engl J Med"},{"issue":"20","key":"2019_CR33","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1182\/blood-2013-05-504043","volume":"122","author":"J Golay","year":"2013","unstructured":"Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482\u201391. https:\/\/doi.org\/10.1182\/blood-2013-05-504043.","journal-title":"Blood"},{"issue":"11","key":"2019_CR34","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1002\/art.38798","volume":"66","author":"JD Jones","year":"2014","unstructured":"Jones JD, Hamilton BJ, Skopelja S, et al. Induction of interleukin-6 production by rituximab in human B cells. Arthritis Rheumatol. 2014;66(11):2938\u201346. https:\/\/doi.org\/10.1002\/art.38798.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"2019_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","volume":"35","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, O\u2019Brien SM, Sweeney ML, et al. Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs. 2021;35(9):985\u201397. https:\/\/doi.org\/10.1007\/s40263-021-00843-8.","journal-title":"CNS Drugs"},{"issue":"9","key":"2019_CR36","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201956.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2019_CR37","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","volume":"78","author":"A Patel","year":"2021","unstructured":"Patel A, Sul J, Gordon ML, et al. Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol. 2021;78(6):736\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0627.","journal-title":"JAMA Neurol"},{"issue":"8","key":"2019_CR38","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/s2352-3026(21)00167-8","volume":"8","author":"CL Bennett","year":"2021","unstructured":"Bennett CL, Focosi D, Socal MP, et al. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. Lancet Haematol. 2021;8(8):e593\u2013604. https:\/\/doi.org\/10.1016\/s2352-3026(21)00167-8.","journal-title":"Lancet Haematol"},{"key":"2019_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120459","volume":"443","author":"K Sharma","year":"2022","unstructured":"Sharma K, Tolaymat S, Yu H, et al. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review. J Neurol Sci. 2022;443:120459. https:\/\/doi.org\/10.1016\/j.jns.2022.120459.","journal-title":"J Neurol Sci"},{"issue":"12","key":"2019_CR40","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","volume":"5","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD, et al. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624\u201343. https:\/\/doi.org\/10.1182\/bloodadvances.2021004629.","journal-title":"Blood Adv"},{"issue":"9","key":"2019_CR41","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1007\/s00415-024-12581-0","volume":"271","author":"AS Karl","year":"2024","unstructured":"Karl AS, Klimas R, Katsimpoura M, et al. Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study. J Neurol. 2024;271(9):6080\u20138. https:\/\/doi.org\/10.1007\/s00415-024-12581-0.","journal-title":"J Neurol"},{"issue":"1","key":"2019_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bjd.21055","volume":"187","author":"AE Macbeth","year":"2022","unstructured":"Macbeth AE, Holmes S, Harries M, et al. The associated burden of mental health conditions in alopecia areata: a population-based study in UK primary care. Br J Dermatol. 2022;187(1):73\u201381. https:\/\/doi.org\/10.1111\/bjd.21055.","journal-title":"Br J Dermatol"},{"key":"2019_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18926","author":"A Muntyanu","year":"2023","unstructured":"Muntyanu A, Gabrielli S, Donovan J, et al. The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.18926.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2019_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/2050313x20919614","volume":"8","author":"LD Chin","year":"2020","unstructured":"Chin LD, AbuHilal M. Ocrelizumab-induced alopecia areata-A series of five patients from Ontario, Canada: a case report. SAGE Open Med Case Rep. 2020;8:2050313x20919614. https:\/\/doi.org\/10.1177\/2050313x20919614.","journal-title":"SAGE Open Med Case Rep"},{"issue":"12","key":"2019_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70028","volume":"27","author":"M Mahyad","year":"2024","unstructured":"Mahyad M, Baghaei M, Baghaei A, et al. Alopecia universalis in a multiple sclerosis patient after switching from Rituximab to Ocrelizumab: a case report. Int J Rheum Dis. 2024;27(12):e70028. https:\/\/doi.org\/10.1111\/1756-185x.70028.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2019_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2017.04.1141.","journal-title":"J Am Acad Dermatol"},{"key":"2019_CR47","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.msard.2018.12.005","volume":"27","author":"C Alcal\u00e1","year":"2019","unstructured":"Alcal\u00e1 C, Pz\u00e9re-Miralles F, Gasc\u00f3n F, et al. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: a secondary autoimmune disease. Mult Scler Relat Disord. 2019;27:406\u20138. https:\/\/doi.org\/10.1016\/j.msard.2018.12.005.","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"2019_CR48","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/ijd.12808","volume":"55","author":"MA Atwa","year":"2016","unstructured":"Atwa MA, Youssef N, Bayoumy NM. T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-\u03b1) in patients with alopecia areata: association with clinical type and severity. Int J Dermatol. 2016;55(6):666\u201372. https:\/\/doi.org\/10.1111\/ijd.12808.","journal-title":"Int J Dermatol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02019-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:08:08Z","timestamp":1763554088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2019"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02019-6","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Because the FAERS database is publicly available and no patient can be identified, ethical approval was not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}